BBH
VanEck Biotech ETF
BBH
VanEck Biotech ETF
-
NAV$195.75
as of December 04, 2025 -
YTD RETURNS24.75%
as of December 04, 2025 -
Total Net Assets$388.87M
as of December 04, 2025 -
Total Expense Ratio0.35%
-
Inception Date12/20/2011
About BBH
VanEck Biotech ETF (BBH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Biotech 25 Index (MVBBHTR), which is intended to track the overall performance of companies involved in the development and production, marketing and sales of drugs based on genetic analysis and diagnostic equipment.
Overview
Why BBH
- Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market cap and trading volume
- Industry Leaders: Index methodology favors the largest companies in the industry
- Global Scope: Portfolio may include both domestic and U.S. listed foreign companies allowing for enhanced industry representation
Performance
Performance History:
Average Annual Total Returns* (%)| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
|---|---|---|---|---|---|---|---|---|
| BBH (NAV) | 9.14 | 19.64 | 25.96 | 19.18 | 6.18 | 3.63 | 5.18 | 13.52 |
| BBH (Share Price) | 9.19 | 19.74 | 26.01 | 19.11 | 6.15 | 3.65 | 5.18 | 13.53 |
| MVBBHTR (Index) | 9.14 | 19.69 | 26.02 | 19.25 | 6.26 | 3.74 | 5.32 | 13.68 |
| Performance Differential (NAV - Index) | -- | -0.05 | -0.06 | -0.07 | -0.08 | -0.11 | -0.14 | -0.16 |
| 1 MO | 3 MO | YTD | 1 YR | 3 YR | 5 YR | 10 YR |
LIFE 12/20/11 |
|
|---|---|---|---|---|---|---|---|---|
| BBH (NAV) | 0.28 | 8.06 | 5.58 | -5.93 | 6.21 | 0.90 | 4.20 | 12.25 |
| BBH (Share Price) | 0.31 | 8.09 | 5.55 | -5.86 | 6.17 | 0.89 | 4.22 | 12.25 |
| MVBBHTR (Index) | 0.29 | 8.07 | 5.60 | -5.88 | 6.30 | 1.01 | 4.34 | 12.41 |
| Performance Differential (NAV - Index) | -0.01 | -0.01 | -0.02 | -0.05 | -0.09 | -0.11 | -0.14 | -0.16 |
$-1.38
/
-0.70%
Fees
Holdings
Daily Holdings (%) as of 12/04/2025
Download XLS|
Ticker
|
Holding Name |
% of Net Assets |
Identifier (FIGI)
|
Shares
|
Asset Class |
Market Value (US$) |
Notional Value |
|---|---|---|---|---|---|---|---|
|
AMGN US |
Amgen Inc | 13.10 |
BBG000BBS2Y0 |
149,804 |
Stock | 50,957,329 | -- |
|
GILD US |
Gilead Sciences Inc | 11.52 |
BBG000CKGBP2 |
365,275 |
Stock | 44,790,021 | -- |
|
VRTX US |
Vertex Pharmaceuticals Inc | 9.36 |
BBG000C1S2X2 |
79,611 |
Stock | 36,410,887 | -- |
|
REGN US |
Regeneron Pharmaceuticals Inc | 5.48 |
BBG000C734W3 |
29,492 |
Stock | 21,316,818 | -- |
|
INSM US |
Insmed Inc | 5.33 |
BBG000BWM5P3 |
101,103 |
Stock | 20,730,159 | -- |
|
NTRA US |
Natera Inc | 5.29 |
BBG001J1BQ86 |
85,049 |
Stock | 20,586,961 | -- |
|
ARGX US |
Argenx Se | 5.06 |
BBG00GHB88X9 |
21,490 |
Stock | 19,684,195 | -- |
|
IQV US |
Iqvia Holdings Inc | 4.64 |
BBG00333FYS2 |
80,241 |
Stock | 18,047,806 | -- |
|
ALNY US |
Alnylam Pharmaceuticals Inc | 4.18 |
BBG000BFGNJ5 |
34,929 |
Stock | 16,253,861 | -- |
|
ONC US |
Beone Medicines Ltd | 3.86 |
BBG00B6WF7T5 |
45,276 |
Stock | 15,004,466 | -- |
|
BIIB US |
Biogen Inc | 3.66 |
BBG000C17X76 |
78,231 |
Stock | 14,236,477 | -- |
|
UTHR US |
United Therapeutics Corp | 3.49 |
BBG000BV4XJ1 |
28,026 |
Stock | 13,567,387 | -- |
|
ICLR US |
Icon Plc | 3.04 |
BBG000CTSZQ6 |
63,588 |
Stock | 11,812,743 | -- |
|
ILMN US |
Illumina Inc | 2.87 |
BBG000DSMS70 |
87,299 |
Stock | 11,176,891 | -- |
|
NBIX US |
Neurocrine Biosciences Inc | 2.37 |
BBG000GJS7C1 |
59,749 |
Stock | 9,214,491 | -- |
|
INCY US |
Incyte Corp | 2.26 |
BBG000BNPSQ9 |
87,392 |
Stock | 8,779,400 | -- |
|
EXAS US |
Exact Sciences Corp | 2.25 |
BBG000CWL0F5 |
86,353 |
Stock | 8,732,879 | -- |
|
BNTX US |
Biontech Se | 1.97 |
BBG00Q70B3V1 |
79,789 |
Stock | 7,659,744 | -- |
|
QGEN US |
Qiagen Nv | 1.61 |
BBG000GTYWL7 |
133,013 |
Stock | 6,262,252 | -- |
|
TECH US |
Bio-Techne Corp | 1.58 |
BBG000C15114 |
96,391 |
Stock | 6,124,684 | -- |
|
TEM US |
Tempus Ai Inc | 1.54 |
BBG01MZQYJF9 |
78,391 |
Stock | 5,983,585 | -- |
|
MRNA US |
Moderna Inc | 1.54 |
BBG003PHHZT1 |
234,401 |
Stock | 5,974,881 | -- |
|
RGEN US |
Repligen Corp | 1.34 |
BBG000BS48J3 |
31,477 |
Stock | 5,217,628 | -- |
|
CRL US |
Charles River Laboratories Internationa | 1.32 |
BBG000BG5BL8 |
27,952 |
Stock | 5,144,286 | -- |
|
BMRN US |
Biomarin Pharmaceutical Inc | 1.26 |
BBG000CZWZ05 |
90,885 |
Stock | 4,891,431 | -- |
|
-USD CASH- |
0.01 |
-- |
24,502 |
Cash Bal | 24,502 | -- | |
|
-- |
Other/Cash | 0.07 |
-- |
0 |
Cash | 279,450 | -- |
Portfolio
Sector Weightings (%) as at 11/30/2025
-
Sector
% of Net Assets -
Health Care
99.92 -
Other/Cash
0.08
Country Weightings (%) as at 11/30/2025
-
Country
% of Net Assets -
United States
90.90 -
China
3.93 -
Ireland
3.00 -
Germany
2.10 -
Other/Cash
0.08
Distributions
Yields as of 12/04/2025
Annual
0.37%
0.64%
0.64%
Distribution History
| Year | Ex-date |
Record Date |
Payable date |
Dividend Income‡ |
Short-Term Capital Gains |
Long-Term Capital Gains |
Return of Capital |
Total Distributions |
|---|---|---|---|---|---|---|---|---|
| 2024 | 12/23/2024 | 12/23/2024 | 12/24/2024 | $ 1.2517 | -- | -- | -- | $ 1.25 |
| 2023 | 12/18/2023 | 12/19/2023 | 12/22/2023 | $ 0.7127 | -- | -- | -- | $ 0.71 |
| 2022 | 12/19/2022 | 12/20/2022 | 12/23/2022 | $ 0.7488 | -- | -- | -- | $ 0.75 |
| 2021 | 12/20/2021 | 12/21/2021 | 12/27/2021 | $ 0.3972 | -- | -- | -- | $ 0.40 |
| 2020 | 12/21/2020 | 12/22/2020 | 12/28/2020 | $ 0.6079 | -- | -- | -- | $ 0.61 |
| 2019 | 12/23/2019 | 12/24/2019 | 12/30/2019 | $ 0.4724 | -- | -- | -- | $ 0.47 |
| 2018 | 12/20/2018 | 12/21/2018 | 12/27/2018 | $ 0.5510 | -- | -- | -- | $ 0.55 |
| 2017 | 12/18/2017 | 12/19/2017 | 12/22/2017 | $ 0.6830 | -- | -- | -- | $ 0.68 |
| 2016 | 12/19/2016 | 12/21/2016 | 12/23/2016 | $ 0.3270 | -- | -- | -- | $ 0.33 |
| 2015 | 12/21/2015 | 12/23/2015 | 12/28/2015 | $ 0.3370 | -- | -- | -- | $ 0.34 |
| 2014 | 12/22/2014 | 12/24/2014 | 12/29/2014 | -- | -- | -- | -- | $ 0.00 |
| 2013 | 12/23/2013 | 12/26/2013 | 12/30/2013 | $ 0.0030 | -- | -- | -- | $ 0.00 |
| 2012 | 12/24/2012 | 12/27/2012 | 12/31/2012 | $ 0.0180 | $ 0.1660 | -- | -- | $ 0.18 |
| 2011 | 12/23/2011 | 12/28/2011 | 12/30/2011 | -- | -- | -- | -- | $ 0.00 |
‡All registered investment companies are obliged to distribute portfolio gains to shareholders at yearend regardless of performance. Trading VanEck ETFs will also generate tax consequences and transaction expenses. The information provided is not intended to be tax advice. Tax consequences of dividend distributions may vary by individual taxpayer. There is no guarantee that dividends will be paid. To receive a distribution, you must have been a registered shareholder of the relevant VanEck ETFs on the record date. Distributions are paid to shareholders on the payment date. Past distributions are not indicative of future distributions.
Certain distributions may constitute a return of capital, which will have the effect of reducing your cost basis in the Fund’s shares and thereby increasing the amount of capital gain, if any, or decreasing the amount of capital loss, if any, that you will realize when selling or exchanging Fund shares. The final determination of the tax characteristics cannot be determined until after each Fund’s yearend and are reported to shareholders on Form 1099-DIV. The form is mailed to shareholders shortly after calendar yearend specifying how the distributions paid by the Fund during the prior calendar year should be characterized for purposes of reporting the distribution on a shareholder’s tax return.
The tax treatment and characterization of the Fund’s distributions may vary significantly from time to time depending on whether the Fund has gains or losses on the securities in its portfolio. The Fund’s distributions will normally reflect past and projected net investment income, and may include income from dividends and interest, capital gains and/or a return of capital. The final composition of the tax characteristics of the distributions cannot be determined with certainty until after the end of the year, and will be reported to shareholders at that time. The amount of distributions will vary, depending on a number of factors. As portfolio and market conditions change, the rate of dividends may change. There can be no assurance that the Fund will be able to declare a dividend distribution in each period. Past performance is no guarantee of future results.